188 related articles for article (PubMed ID: 37903072)
1. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
Kawsar A; Hussain K; Muinonen-Martin AJ; Fearfield L
Br J Dermatol; 2023 Oct; 189(Suppl 1):i3-i10. PubMed ID: 37903072
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
3. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
4. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
Apalla Z; Nikolaou V; Fattore D; Fabbrocini G; Freites-Martinez A; Sollena P; Lacouture M; Kraehenbuehl L; Stratigos A; Peris K; Lazaridou E; Richert B; Vigarios E; Riganti J; Baroudjian B; Filoni A; Dodiuk-Gad R; Lebbé C; Sibaud V
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):332-350. PubMed ID: 34910332
[TBL] [Abstract][Full Text] [Related]
5. Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review.
Juan-Carpena G; Palazón-Cabanes JC; Blanes-Martínez M
Actas Dermosifiliogr; 2022 Apr; 113(4):376-387. PubMed ID: 35623728
[TBL] [Abstract][Full Text] [Related]
6. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Wongvibulsin S; Pahalyants V; Kalinich M; Murphy W; Yu KH; Wang F; Chen ST; Reynolds K; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2022 Mar; 86(3):563-572. PubMed ID: 33819538
[TBL] [Abstract][Full Text] [Related]
8. Management of immune checkpoint inhibitor-related dermatologic adverse events.
Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
[TBL] [Abstract][Full Text] [Related]
9. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse events caused by immune checkpoint inhibitors.
Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
Storgard R; Markova A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous manifestations associated with immune checkpoint inhibitors.
Watanabe T; Yamaguchi Y
Front Immunol; 2023; 14():1071983. PubMed ID: 36891313
[TBL] [Abstract][Full Text] [Related]
15. [Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review].
Gomes N; Sibaud V; Azevedo F; Magina S
Acta Med Port; 2020 May; 33(5):335-343. PubMed ID: 32416756
[TBL] [Abstract][Full Text] [Related]
16. Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
Klein BA; Alves FA; de Santana Rodrigues Velho J; Vacharotayangul P; Hanna GJ; LeBoeuf NR; Shazib MA; Villa A; Woo SB; Sroussi H; Sonis S; Treister NS
Oral Dis; 2022 Jan; 28(1):9-22. PubMed ID: 34265157
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
Keiser MF; Patel AB; Altan M
Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
[TBL] [Abstract][Full Text] [Related]
18. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
Nadelmann ER; Yeh JE; Chen ST
JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
[TBL] [Abstract][Full Text] [Related]
19. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
20. Mucocutaneous adverse events to immune checkpoint inhibitors.
Muhaj F; Karri PV; Moody W; Brown A; Patel AB
Front Allergy; 2023; 4():1147513. PubMed ID: 36938327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
